Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements

Executive Summary

Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.

You may also be interested in...



COVID-19 Supplement Approvals Jump, Some On-Time Decision Rates Slip For US FDA

In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.

PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals

Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.

US GDUFA III Talks In Final Stages, Agreement Nearly Complete

Final commitment letter preparations now under way as revenue issues are resolved.

Related Content

Topics

UsernamePublicRestriction

Register

PS144888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel